FDAsafety guidance66% confidence
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for MEDUNIK; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Metabolic Disorders · Urea Cycle Disorders
- Sub-indication
- General
Related signal: FDA Approves Supplement for PHEBURANE (NDA216513) by MEDUNIK